One-year Safety and Effectiveness of Ustekinumab in Patients With Crohn's Disease: The K-STAR Study.
Chang Kyun LeeWon MoonJaeyoung ChunEun Soo KimHyung Wook KimHyuk YoonHyun Soo KimYoo Jin LeeChang Hwan ChoiYunho JungSung Chul ParkGeun Am SongJong Hun LeeEun Suk JungYoungdoe KimSu Young JungJong Min ChoiByong Duk YePublished in: Inflammatory bowel diseases (2024)
Ustekinumab was well-tolerated, effective, and safe as induction and maintenance therapy for CD in Korea.